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Epidemiology of the Influenza A Virus H5N1 Subtype and Memory of
Immunity to the H2N2 Subtype
In their recent paper, Peter Palese and Taia T. Wang proposed ahypothesis to explain how an older circulating subtype of influ-
enza A virus is replaced with a novel subtype (1). They and others
also published experimental evidence supporting their hypothesis
on the extinction of seasonal H1N1 viruses by the 2009 pandemic
H1N1 viruses (2). Although they discussed only the disappearance
of seasonal H1N1 and H2N2 subtypes, we think that the same
mechanism may be working against the currently circulating
H5N1 subtype.
The World Health Organization had reported a skewed age
distribution of confirmed H5N1 cases in 2006 (3), and Matthew
Smallman-Raynor and Andrew D. Cliff suggested the possibility
that persons born before 1969 have immunity to the H5N1 sub-
type, which may be associated with geographically widespread in-
fluenza A events before the late 1960s (they also mentioned other
behavioral and biological factors which can account for the ob-
served skewing) (4). An obvious candidate for geographically
widespread influenza A events before the late 1960s is the H2N2
pandemic in 1957, in which the seasonal H1N1 subtype, having
circulated since 1918, was replaced by the H2N2 subtype (5).
Palese and Wang (1) suggested that “the induction of cross-
neutralizing antibodies directed against the stalk of the H1 hem-
agglutinin following infection with the related group 1 virus
(H2N2) played a significant role in the protection of older seg-
ments of the population from disease in 1957 and in the elimina-
tion of the existing seasonalH1N1 virus.” Phylogenetically, theH2
hemagglutinin is closer to H5 hemagglutinin, which also belongs
to group 1 (6), than to theH1 hemagglutinin when entire proteins
are compared (7) and when the HA2 domains are compared (8).
Therefore, the stalk-specific antibodies induced against the H2
subtype from 1957 to 1968 may be more cross-reactive to the H5
subtype and may have rendered the population born before 1968
more resistant to H5N1 subtypes than that born after 1968, who
have experienced only seasonal H1N1 and H3N2 subtypes.
The subjects in the Smallman-Raynor and Cliff paper were
likely to have been exposed to both subtypes (4); therefore, it is not
possible to know the impact of exposure to seasonal H1N1 and
H3N2 subtypes on resistance to the H5N1 subtype. However, be-
cause the H3 hemagglutinin belongs to group 2, the stalk-specific
antibodies produced against H3 are less likely to be cross-reactive
to group 1 hemagglutinins, including H5 (although there are re-
ports of monoclonal antibodies in humans which can bind to
group 1 hemagglutinins and some, not all, H3 hemagglutinins [9,
10], they are likely to be rarer than group-specific antibodies),
suggesting that they do not contribute much to the resistance to
H5N1.
Pica et al. showed that natural infection with the 2009 pan-
demic H1N1 strain boosted the titers of stalk-specific antibodies
in humans (2); however, the seasonal vaccine (the inactivated
2008-2009 trivalent vaccine not containing the 2009 pandemic
H1N1 hemagglutinin) did not (11). Other groups also found that
vaccination with the inactivated 2009 pandemic H1N1 vaccine
induced the stalk-specific antibodies efficiently (12-14). Some of
the stalk-specific monoclonal antibodies reported to date are
cross-reactive to both 2009 pandemic H1N1 andH5N1 strains (9,
10, 13, 15). Therefore, we speculate that natural infection or vac-
cination with the pandemic 2009 H1N1 strain may make us more
resistant to viruses of the H5N1 subtype because of these stalk-
specific antibodies.
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